[Reporter's view] Disclosure of the results of the Committee

The results of the Cancer Drugs Benefit Appraisal Committee were released from the 13th.

 

The HIRA has accepted complaints continuously filed in the pharmaceutical industry.

 

Some point out that they are not satisfied yet, but it can be said that it is encouraging in itself because the HIRA expressed its intention to deliver the exact reason for the success at the request of the company.

 

In the pharmaceutical industry, discussions on expanding insurance benefits for new drugs have been focused on the Cancer Drugs Benefit Appraisal Committee along with the COVID-19 incident.The Cancer Drugs Benefit Appraisal Committee, which was discussing the clinical usefulness of drugs, began examining the financial burden last year.

 

Since then, as more and more drugs are pending in the pharmaceutical industry due to the Cancer Drugs Benefit Appraisal Committee, even companies have submitted economic evaluation data to the subcommittee.

 

Of course, there may have been many pharmaceutical companies that were greedy last year, and there may have been many drugs that were not clinically useful.

 

So the industry's argument was focused on transparency.

 

This was not a necessary procedure only for the pharmaceutical industry.

 

This is because knowing which drugs have been judged to be unsuitable for what reason, greedy pharmaceutical companies can be criticized and make efforts to find a compromise.

 

Of course, the disclosure of the details of the discussion is 'not yet', but the transparency of the committee has risen to the first level.

 

Beyond the pharmaceutical industry, the healthcare industry is facing a new era.

 

Patients, or their families, now search for surgical papers and search for new drug information in the clinical trial database clinic at clinicaltrial.gov.

 

If domestic licensed drugs do not receive insurance benefits, complaints will pour out to the relevant ministries, the HIRA and the MOHW.

 

The anger of patients and their families looking at "the medicine that exists but cannot be taken" is indescribable.

 

The urgency that cannot be estimated unless it is a party, the level of knowledge of the people who have risen, and the administrative power resulting from the development of the Internet are amazing.

 

Transparency in the process of listing or expanding insurance benefits for new drugs will gradually increase in the future.

 

Both the government and pharmaceutical companies should now fear social views that include desperation.

 

The disclosure of the results of the Cancer Drugs Benefit Appraisal Committee is welcome for now.